metabolic anomolies associated with the 6 month clinical evolution of patients suffering from motor conversion disorder

Conditions: Conversion Disorder

Summary: the main objective of this study is to make a first evaluation of the relationship between metabolic abnormalities objectified by positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- d-glucose integrated with computed tomography (pet ct 18 fdh) performed at rest at the onset of symptoms in patients with a first episode of motor conversion disorder and the persistence of a motor disability at 6 months measured by the modified rankin score (mrs).

the secondary objectives of this study are: a. to assess whether metabolic abnormalities objectified by pet ct 18 fdh performed at rest at the onset of symptoms may be predictive of persistent disability at 6 months as measured by the edss, the nihss and who status. b. to assess whether metabolic abnormalities objectified by pet ct 18 fdh performed at rest at 3 months after diagnosis may be predictive of persistent motor disability at 6 months (edss, nihss, mrs, who) c. to search for and characterize any abnormalities of metabolism objectified in the initial pet ct 18 fdh predictive of persistent motor disability at 3 months. d. to determine if there are persistent metabolic abnormalities 3 months post-diagnosis independently of the clinical course (marker trait). e. define the brain areas whose metabolism is often altered in patients with motor conversion disorders. f. establish a collection of biological samples from patients for future research studies of prognostic biomarkers of a motor conversion disorder.

Eligibility criteria:
inclusion criteria: * the patient must have given free and informed consent and signed the consent * the patient must be affiliated with or beneficiary of a health insurance plan * the patient meets dsm-iv criteria for motor conversion disorder (with paralysis, motor weakness or abnormal movements) lasting for less than 1 month and euthymic (hamd score \< or = 7, as evaluated by a psychiatrist) * first episode (incident cases) * the latest symptom dates to within a month * the patient is not under neuroleptics exclusion criteria: * the subject is participating in another study * the subject is in an exclusion period determined by a previous study * the subject is under judicial protection, guardianship or curatorship * the subject refuses to sign the consent * it is not possible to correctly inform the patient * the patient is pregnant, parturient or she is breastfeeding * specialized clinical neurological examination and brain and spinal cord mri revealed an organic neurological cause * the subject has a hamd score \> 7 * the subject currently has manic/hypomanic episode, a diagnosis of substance abuse or dependency (excluding tobacco), a diagnosis of schizophrenia (any time in the past) or chronic neurological disease (active epilepsy, stroke, brain tumor) * suicidal or high risk for suicide (according to mini assessment) * contra-indication for a pet scan * patient under neuroleptics at inclusion * the last symptom happened over 1 month ago * the patient has had previous episodes (prevalent cases)